Victory Capital Management Inc. Grows Position in Janux Therapeutics, Inc. (NASDAQ:JANX)

Victory Capital Management Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX) by 143.4% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 29,745 shares of the company’s stock after buying an additional 17,525 shares during the period. Victory Capital Management Inc. owned 0.06% of Janux Therapeutics worth $1,351,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Chicago Partners Investment Group LLC purchased a new position in Janux Therapeutics in the 3rd quarter worth $239,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Janux Therapeutics by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 10,033 shares of the company’s stock worth $456,000 after purchasing an additional 3,943 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in shares of Janux Therapeutics by 639.5% in the third quarter. Nisa Investment Advisors LLC now owns 20,343 shares of the company’s stock worth $924,000 after purchasing an additional 17,592 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Janux Therapeutics by 21.9% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company’s stock worth $87,000 after purchasing an additional 339 shares during the period. Finally, Point72 Asset Management L.P. purchased a new stake in Janux Therapeutics in the second quarter valued at approximately $5,715,000. 75.39% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $63.00 price objective on shares of Janux Therapeutics in a report on Thursday, November 7th. Leerink Partnrs upgraded Janux Therapeutics to a “strong-buy” rating in a research report on Friday. Stifel Nicolaus initiated coverage on shares of Janux Therapeutics in a report on Friday, September 6th. They set a “buy” rating and a $70.00 target price for the company. UBS Group started coverage on shares of Janux Therapeutics in a report on Thursday, October 24th. They set a “buy” rating and a $69.00 price target on the stock. Finally, Wedbush restated an “outperform” rating and set a $74.00 price target on shares of Janux Therapeutics in a research report on Thursday, August 8th. One investment analyst has rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $67.70.

Janux Therapeutics Stock Down 3.0 %

JANX opened at $48.82 on Tuesday. The company has a market cap of $2.56 billion, a PE ratio of -41.73 and a beta of 3.52. Janux Therapeutics, Inc. has a twelve month low of $7.79 and a twelve month high of $65.60. The company has a 50-day moving average price of $50.05 and a 200 day moving average price of $45.83.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.18). The firm had revenue of $0.44 million for the quarter, compared to analysts’ expectations of $1.50 million. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. The company’s quarterly revenue was down 82.6% on a year-over-year basis. As a group, sell-side analysts expect that Janux Therapeutics, Inc. will post -1.34 earnings per share for the current year.

Insider Buying and Selling

In other Janux Therapeutics news, major shareholder Ventures Xi L.P. Avalon sold 2,182 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $42.33, for a total value of $92,364.06. Following the transaction, the insider now directly owns 7,000 shares of the company’s stock, valued at $296,310. This trade represents a 23.76 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Andrew Hollman Meyer sold 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 27th. The shares were sold at an average price of $45.96, for a total value of $2,298,000.00. Following the completion of the sale, the insider now owns 67,592 shares of the company’s stock, valued at $3,106,528.32. This trade represents a 42.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 420,610 shares of company stock worth $19,288,666. 29.40% of the stock is owned by corporate insiders.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.